ACS — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Use of strong CYP3A4 inhibitors
Ticagrelor is metabolised by CYP3A4, and concomitant use with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin) or inducers (e.g. rifampicin) is contraindicated. This does not apply to clopidogrel, which is metabolised by CYP2C19. History of intracranial haemorrhage and active bleeding are contraindications to both agents.
Reference: AMH – 2025 – Antiplatelet agents; eTG – 2025 – Cardiovascular